COVID-19 may manifest as mild, moderate or severe disease with each grade of severity having its own features and post-viral implications. With the rising burden of the pandemic, it is vital to identify not only active disease but any post-recovery complications as well. This study was conducted with the aim of identifying the presence of post-viral symptomatology in patients recovered from mild COVID-19 disease. Presence or absence of 11 post-viral symptoms was recorded and we found that 8 of the 11 studied symptoms were notably more prevalent amongst the female sample population. Our results validate the presence of prolonged symptoms months after recovery from mild COVID-19 disease, particularly in association with the female gender. Hence, proving the post-COVID syndrome is a recognizable diagnosis in the bigger context of the post-viral fatigue syndrome.

COVID-19 may manifest as mild, moderate or severe disease with each grade of severity having its own features and post-viral implications. With the rising burden of the pandemic, it is vital to identify not only active disease but any post-recovery complications as well.This study was conducted with the aim of identifying the presence of post-viral symptomatology in patients recovered from mild COVID-19 disease. Presence or absence of eleven post viral symptoms was recorded and we found that eight of the eleven studied symptoms were notably more prevalent amongst the female sample population. Our results validate the presence of prolonged symptoms months after recovery from mild COVID-19 disease, particularly in association with the female gender. Hence, proving the post-COVID syndrome is a recognizable diagnosis in the bigger context of the post-viral fatigue syndrome.

Introduction Squamous cell carcinoma arising at the maxillary sinus is a rare neoplasm, characterized by an aggressive growth pattern and glooming prognosis. The proximity of the maxillary sinus with complex anatomical structures such as the eye, skull base, infratemporal fossa, pterygomaxillary fossa, nasal cavities, and ethmoid sinuses makes the surgical treatment of tumors infiltrating into these structures very challenging. The study's objective was to investigate the prognostic factors of survival and maxillary sinus SCC treatment outcomes. Methods We did a retrospective analysis of patients treated for maxillary sinus SCC at our institution between 2004 -2018. The study included all the patients with histologically proven maxillary sinus SCC treated with curative intent. The medical record of 43 patients was reviewed and utilized for the analysis. The Kaplan-Meier curve calculated five-year overall survival. Results A total of 43 patients were analyzed. At the presentation time, the mean age was 54.56 years (SD ± 11.65). Smoking (n=13, 30.2%) was the common risk factor. 36 (83.7%) patients presented with stage IV disease. Surgery was performed in 16 (37.2%) patients, whereas 27 (62.8%) patients received radiation and chemotherapy. Treatment failure was seen in 35 (81.4%) patients with locoregional recurrence in 30 (85.7%) patients and distant metastases in 5 (14.3%) patients. The five years overall survival in our study was 22%. Loco-regional recurrence and distant metastasis were the significant factors impacting survival (p=0.01). Conclusion Maxillary sinus SCC is rare cancer that is more common in males and usually presents at an advanced stage with a poor outcome. These tumors have a higher rate of treatment failure with a poor prognosis. Locoregional recurrence and distant metastasis adversely impact the overall survival.

No abstract

an NGS panel, identifying challenges in case classification and possible solutions. Methodology We performed the FoundationOne CDx NGS panel on 60 EC and assigned molecular subtype: POLE mutated (POLEmut), mismatch repair deficient (MMRd), p53 abnormal (p53abn) or no specific molecular subtype (NSMP). Result(s)* In 55 patients the molecular classification was successful. A pathogenic POLE mutation was detected in 9 cases (POLEmut). 20 were MMRd (12 MSI-high, 8 MSI-indeterminate based on the NGS panel MSI classifier) and a known or likely MMR gene mutation was found in 7 of these. Of the remaining 26 cases, 17 carried a TP53 mutation (p53abn) and the remaining 9 were considered to be NSMP. The tumor mutation burden (TMB) was significantly different (p<0.001) in the molecular subtypes (A) and high TMB (>55 mut/MB) was 100% specific for POLEmut EC (p<0.001). High TMB was specific for known pathogenic POLE mutations and was not elevated in cases with solely non-pathogenic POLE mutations (B).In non-POLEmut cases, TMB was higher in MSI-high and MSI-indeterminate than microsatellite stable (MSS) cases (C), and a TMB of >7 mut/MB was 100% specific for MMRd EC. There was one MSS EC with a TMB of 18 mut/MB but it showed loss of MLH1 and PMS2 proteins on immunostaining and was classified as MMRd. Conclusion* An NGS panel can be used in the molecular classification of EC when there is sufficient tumor cellularity. TMB can be used as an adjunct in molecular subtype diagnosis for tumors that are difficult to classify. Additionally, TMB can potentially serve as a diagnostic adjunct in cases with POLE mutation of unknown significance.